Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Guided Therapeutics, Inc. (GTHP) Message Board

November 01, 2018 Indonesia Places New Orders f

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 117
(Total Views: 646)
Posted On: 11/01/2018 10:33:16 PM
Avatar
Posted By: CyberC
November 01, 2018

Indonesia Places New Orders for High Margin LuViva Advanced Cervical Scan Single Use Cervical Guides



Contacts
Guided Therapeutics
Mark Faupel
mfaupel@guidedinc.com

Guided Therapeutics, Inc. (OTCQB: GTHP) reported today that its distribution partner for Indonesia, the world’s fourth largest country, placed a fully paid order for 2,000 high margin, single use Cervical Guides, to be used with the existing installed base of LuViva® Advanced Cervical Scans. The purchase announced today, which includes only high-margin Cervical Guides, further indicates that installed LuViva units are seeing increased usage in hospitals and clinics, and bolsters reports that medical practitioners in Indonesia are comfortable using the LuViva test as an alternative to conventional for cervical cancer screening. This most recent orders marks the ninth time LuViva equipment has been ordered for Indonesia, with total sales revenue over $350,000; 60% of which has shipped within the past year.

“We are very encouraged that usage of LuViva in Indonesia is increasing, as clinics and hospitals are seeing the benefit of screening with LuViva, which provides an immediate result so that treatment, if needed, can begin more quickly,” said Gene Cartwright, CEO. “The increase in sales of the high margin Cervical Guides per installed device is an important component to reaching profitability. It also is an indicator of the overall satisfaction doctors, their clinics and patients have with our product.”

There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide. The world market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and subsequent filings.


View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005546/en/

News powered by iR Direct — Copyright © 2018 Issuer Direct Corporation.

All Rights Reserved.


(0)
(0)




Guided Therapeutics, Inc. (GTHP) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


WORDS TO LIVE BY:

Never argue with stupid people, they will drag you down to their level and then beat you with experience.


Get .... PrivacyLok https://cyberidguard.com/

Try SafeVchat: https://cyberidguard.com/

My comments are only my opinion and are not to be used for investment advice.

Please conduct your own due diligence before choosing to buy or sell any stock.

xgqbj600g2g.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us